Top 3 Emerging Trends Impacting the Global Anti-Inflammatory Therapeutics Market from 2017-2021: Technavio

Technavio has published a new report on the global anti-inflammatory therapeutics market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???

LONDON--()--Technavio’s latest report on the global anti-inflammatory therapeutics market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

The global anti-inflammatory therapeutics market is a concentrated market with the presence of many small and large vendors. The market is currently witnessing the loss of patents on major blockbuster drugs such as Enbrel, REMICADE, and HUMIRA. This has led to the entry of biosimilars into the market. A biosimilar is a genetically engineered large protein molecule that is derived from living cells or made synthetically using deoxyribose nucleic acid (DNA) recombinant technology. It is highly similar to their reference or original biologic molecule in terms of efficacy and safety.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

The top three emerging trends driving the global anti-inflammatory therapeutics market according to Technavio healthcare and life sciences research analysts are:

  • Emergence of novel anti-inflammatory drugs
  • Increasing strategic alliances by vendors
  • Advent of biosimilars

Emergence of novel anti-inflammatory drugs

Cytokines are proteins produced by immune cells. These protein molecules facilitate communication between cells and play a pivotal role in cell development and differentiation, including regulation of immune response. A large number of mammalian cytokines mediate their action by activating the JAK or signal transducers and activators of transcription pathway,” says Sapna Jha, a lead analyst at Technavio for research on cardiovascular and metabolic disorders.

The JAK/STAT signaling pathway consists of a cell receptor, a JAK enzyme, two signaling transducers, and activator of transducer protein. Inhibition of this pathway causes a decrease in the level of immune response. Therefore, there has been an increased interest in developing drugs targeting JAK/STAT pathway for the treatment of various inflammatory non-malignancy diseases such as IBD and RA.

Increasing strategic alliances by vendors

The global anti-inflammatory therapeutics market is currently witnessing increasing acquisition of anti-inflammatory products by major vendors to expand their business. For instance, in June 2016, Pfizer acquired Anacor Pharmaceuticals. The acquisition gave Pfizer the commercial rights for Anacor Pharmaceuticals’ crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, which was approved by the US FDA in December 2016 under the trade name, Eucrisa.

In April 2015, Pfizer acquired a minority equity interest in AM-Pharma, a Dutch biopharmaceutical company focused on the development of recAP for IMID and secured an exclusive right to acquire the remaining equity in the company,” adds Sapna.

Advent of biosimilars

The introduction of target biological products has revolutionized the management of various IMIDs such as RA, psoriasis, and IBD. After the treatment with biological therapies, many patients experienced improvement in the symptoms of their disease and enhanced productivity in their work life and personal life.

The high cost of biological drugs, in turn, increases the financial burden on the healthcare system and demands reimbursement for these drugs. Due to ineffective reimbursement policy in the developing countries such as India, China, Pakistan, and the Philippines, the lack of patient access to these drugs remains a major concern.

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like life science research tools, in-vitro diagnostics, and cardiovascular devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630-333-9501
UK: +44 208 123 1770

Release Summary

Technavio's report on the global anti-inflammatory therapeutics market analyses the most important trends expected to impact the market outlook.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630-333-9501
UK: +44 208 123 1770